The report analyzes and forecasts the drug delivery systems market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of drug delivery systems, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major drug delivery systems companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of drug delivery systems upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of drug delivery systems and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global drug delivery systems market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the drug delivery systems market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of drug delivery systems market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles the major players operating in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the drug delivery systems market include AstraZeneca plc., Bayer AG, Pfizer Inc., Novartis AG, Amgen Inc., Johnson and Johnson Services, Inc., Baxter International, Inc., Boston Scientific Corporation, and Becton, Dickinson & Company.
The global drug delivery systems market has been segmented as follows:
Drug Delivery Systems Market, by Type of Delivery System
Drug Delivery Systems Market, by Application
Drug Delivery Systems Market, by Route of Administration
Drug Delivery Systems Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Drug Delivery Systems Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Product Overview
4.1.2. Industry Evolution / Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Pipeline Analysis - Drug Therapy Products
4.4. Porter’s Five Force Analysis
4.5. Technological Advancement in Drug Delivery Products
4.6. Regulatory Scenario
4.7. Key Mergers and Acquisitions
4.8. Global Drug Delivery Systems Market Analysis and Forecasts, 2015–2026
4.8.1. Market Revenue Projection (US$ Mn)
4.8.2. Market Outlook
Chapter 5. Global Drug Delivery Systems Market Analysis and Forecasts, by Type of Delivery System
5.1. Key Findings / Developments
5.2. Introduction & Definition
5.3. Market Value Forecast by Delivery Systems, 2017–2026
5.3.1. Intrauterine Implants
5.3.2. Prodrug Implants
5.3.3. Polymeric Drug Delivery
5.3.4. Targeted Drug Delivery
5.4. Market Attractiveness by Delivery Systems
Chapter 6. Global Drug Delivery Systems Market Analysis and Forecasts, by Application
6.1. Key Findings / Developments
6.2. Introduction & Definition
6.3. Market Value and Volume Forecast by Application, 2017–2026
6.3.1. Infectious Diseases
6.3.2. Oncology
6.3.3. Ophthalmology
6.3.4. Urology
6.3.5. Diabetes
6.3.6. CNS
6.3.7. Others
6.4. Market Attractiveness by Application
Chapter 7. Global Drug Delivery Systems Market Analysis and Forecasts, by Route of Administration
7.1. Key Findings / Developments
7.2. Introduction & Definition
7.3. Market Value and Volume Forecast by Route of Administration, 2017–2026
7.3.1. Oral
7.3.2. Injectable
7.3.3. Inhalation
7.3.4. Transdermal
7.3.5. Ocular
7.3.6. Nasal
7.3.7. Topical
7.4. Market Attractiveness by Route of Administration
Chapter 8. Global Drug Delivery Systems Market Analysis and Forecasts, by Geography / Region
8.1. Geographical Representation
8.2. Market Value and Volume Forecast by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness by Region
Chapter 9. North America Drug Delivery Systems Market Analysis and Forecast
9.1. Market Value Forecast by Country, 2017–2026
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Forecast by Type of Delivery System, 2017–2026
9.3. Market Value Forecast by Application, 2017–2026
9.4. Market Value Forecast by Route of Administration, 2017–2026
9.5. Market Attractiveness Analysis
9.5.1. by Country
9.5.2. by Type of Delivery System
9.5.3. by Application
9.5.4. by Route of Administration
Chapter 10. Europe Drug Delivery Systems Market Analysis and Forecast
10.1. Market Value Forecast by Country, 2017–2026
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Forecast by Type of Delivery System, 2017–2026
10.3. Market Value Forecast by Application, 2017–2026
10.4. Market Value Forecast by Route of Administration, 2017–2026
10.5. Market Attractiveness Analysis
10.5.1. by Country
10.5.2. by Type of Delivery System
10.5.3. by Application
10.5.4. by Route of Administration
Chapter 11. Asia Pacific Drug Delivery Systems Market Analysis and Forecast
11.1. Market Value Forecast by Country, 2017–2026
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of APAC
11.2. Market Value Forecast by Type of Delivery System, 2017–2026
11.3. Market Value Forecast by Application, 2017–2026
11.4. Market Value Forecast by Route of Administration, 2017–2026
11.5. Market Attractiveness Analysis
11.5.1. by Country
11.5.2. by Delivery Systems
11.5.3. by Application
11.5.4. by Route of Administration
Chapter 12. Latin America Drug Delivery Systems Market Analysis and Forecast
12.1. Market Value Forecast by Country, 2017–2026
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of LATAM
12.2. Market Value Forecast by Type of Delivery System, 2017–2026
12.3. Market Value Forecast by Application, 2017–2026
12.4. Market Value Forecast by Route of Administration, 2017–2026
12.5. Market Attractiveness Analysis
12.5.1. by Country
12.5.2. by Delivery Systems
12.5.3. by Application
12.5.4. by Route of Administration
Chapter 13. Middle East and Africa Drug Delivery Systems Market Analysis and Forecast
13.1. Market Value Forecast by Country, 2017–2026
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of MEA
13.2. Market Value Forecast by Type of Delivery System, 2017–2026
13.3. Market Value Forecast by Application, 2017–2026
13.4. Market Value Forecast by Route of Administration, 2017–2026
13.5. Market Attractiveness Analysis
13.5.1. by Country
13.5.2. by Delivery Systems
13.5.3. by Application
13.5.4. by Route of Administration
Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. Novartis AG
14.1.2. Amgen Inc.
14.1.3. F. Hoffmann-La Roche Ltd.
14.1.4. Pfizer Inc.
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. Novartis AG (HQ, Business Segments, Employee Strength)
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. Amgen Inc. (HQ, Business Segments, Employee Strength)
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. F.Hoffmann-La Roche Ltd. (HQ, Business Segments, Employee Strength)
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Pfizer Inc. (HQ, Business Segments, Employee Strength)
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Johnson & Johnson Services, ltd. (HQ, Business Segments, Employee Strength)
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. Becton, Dickinson and Company (HQ, Business Segments, Employee Strength)
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. AstraZeneca plc (HQ, Business Segments, Employee Strength)
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Baxter International, Inc. (HQ, Business Segments, Employee Strength)
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. Bayer AG (HQ, Business Segments, Employee Strength)
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Boston Scientific Corporation (HQ, Business Segments, Employee Strength)
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers